Abstract
In Germany, annual therapy cost calculations are required (§35a SGB V) as part of the early benefit assessment of medical products. The Institute for Quality and Efficiency in Health Care (IQWiG), which is usually commissioned to assess the pharmaceutical dossiers, expects high accuracy, consistency, and transparency from presented cost calculations. Standardised automated processes based on automated data extraction or algorithm-based identification of the most appropriate and cost-effective products can help avoid IQWiG criticism.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
